These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 18230035

  • 1. Vaccines for Chlamydia infections of the female genital tract.
    Hafner LM, McNeilly C.
    Future Microbiol; 2008 Feb; 3(1):67-77. PubMed ID: 18230035
    [Abstract] [Full Text] [Related]

  • 2. Chlamydia trachomatis: impact on human reproduction.
    Paavonen J, Eggert-Kruse W.
    Hum Reprod Update; 1999 Feb; 5(5):433-47. PubMed ID: 10582782
    [Abstract] [Full Text] [Related]

  • 3. Chlamydia trachomatis infection control programs: lessons learned and implications for vaccine development.
    Chavez JM, Vicetti Miguel RD, Cherpes TL.
    Infect Dis Obstet Gynecol; 2011 Feb; 2011():754060. PubMed ID: 22144851
    [Abstract] [Full Text] [Related]

  • 4. Live-attenuated influenza viruses as delivery vectors for Chlamydia vaccines.
    He Q, Martinez-Sobrido L, Eko FO, Palese P, Garcia-Sastre A, Lyn D, Okenu D, Bandea C, Ananaba GA, Black CM, Igietseme JU.
    Immunology; 2007 Sep; 122(1):28-37. PubMed ID: 17451464
    [Abstract] [Full Text] [Related]

  • 5. Towards a Chlamydia trachomatis vaccine: how close are we?
    Cochrane M, Armitage CW, O'Meara CP, Beagley KW.
    Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
    [Abstract] [Full Text] [Related]

  • 6. Subclinical chlamydial infection of the female mouse genital tract generates a potent protective immune response: implications for development of live attenuated chlamydial vaccine strains.
    Su H, Messer R, Whitmire W, Hughes S, Caldwell HD.
    Infect Immun; 2000 Jan; 68(1):192-6. PubMed ID: 10603387
    [Abstract] [Full Text] [Related]

  • 7. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
    Agrawal T, Vats V, Salhan S, Mittal A.
    J Reprod Immunol; 2009 Dec; 83(1-2):173-8. PubMed ID: 19896206
    [Abstract] [Full Text] [Related]

  • 8. Development of a Chlamydia trachomatis vaccine for urogenital infections: novel tools and new strategies point to bright future prospects.
    Hafner LM, Timms P.
    Expert Rev Vaccines; 2018 Jan; 17(1):57-69. PubMed ID: 29264970
    [Abstract] [Full Text] [Related]

  • 9. Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge.
    Pal S, Peterson EM, Rappuoli R, Ratti G, de la Maza LM.
    Vaccine; 2006 Feb 06; 24(6):766-75. PubMed ID: 16199110
    [Abstract] [Full Text] [Related]

  • 10. Status of vaccine research and development of vaccines for Chlamydia trachomatis infection.
    Poston TB, Gottlieb SL, Darville T.
    Vaccine; 2019 Nov 28; 37(50):7289-7294. PubMed ID: 28111145
    [Abstract] [Full Text] [Related]

  • 11. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
    Igietseme JU, Eko FO, Black CM.
    Expert Rev Vaccines; 2003 Feb 28; 2(1):129-46. PubMed ID: 12901604
    [Abstract] [Full Text] [Related]

  • 12. Delivery of Chlamydia vaccines.
    Igietseme J, Eko F, He Q, Bandea C, Lubitz W, Garcia-Sastre A, Black C.
    Expert Opin Drug Deliv; 2005 May 28; 2(3):549-62. PubMed ID: 16296774
    [Abstract] [Full Text] [Related]

  • 13. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections.
    Hickey DK, Aldwell FE, Beagley KW.
    Vaccine; 2009 Oct 19; 27(44):6217-25. PubMed ID: 19698810
    [Abstract] [Full Text] [Related]

  • 14. Duration of untreated chlamydial genital infection and factors associated with clearance: review of animal studies.
    Miyairi I, Ramsey KH, Patton DL.
    J Infect Dis; 2010 Jun 15; 201 Suppl 2():S96-103. PubMed ID: 20470047
    [Abstract] [Full Text] [Related]

  • 15. Chlamydia trachomatis: Protective Adaptive Responses and Prospects for a Vaccine.
    Poston TB, Darville T.
    Curr Top Microbiol Immunol; 2018 Jun 15; 412():217-237. PubMed ID: 27033698
    [Abstract] [Full Text] [Related]

  • 16. Vaccination with the polymorphic membrane protein A reduces Chlamydia muridarum induced genital tract pathology.
    Müller T, Becker E, Stallmann S, Waldhuber A, Römmler-Dreher F, Albrecht S, Mohr F, Hegemann JH, Miethke T.
    Vaccine; 2017 May 15; 35(21):2801-2810. PubMed ID: 28413133
    [Abstract] [Full Text] [Related]

  • 17. Risk of sequelae after Chlamydia trachomatis genital infection in women.
    Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB.
    J Infect Dis; 2010 Jun 15; 201 Suppl 2():S134-55. PubMed ID: 20470050
    [Abstract] [Full Text] [Related]

  • 18. The anti-idiotypic antibody to chlamydial glycolipid exoantigen (GLXA) protects mice against genital infection with a human biovar of Chlamydia trachomatis.
    Whittum-Hudson JA, Rudy D, Gèrard H, Vora G, Davis E, Haller PK, Prattis SM, Hudson AP, Saltzman WM, Stuart ES.
    Vaccine; 2001 Jul 16; 19(28-29):4061-71. PubMed ID: 11427283
    [Abstract] [Full Text] [Related]

  • 19. Female genital Chlamydia trachomatis infection: where are we heading?
    Mylonas I.
    Arch Gynecol Obstet; 2012 May 16; 285(5):1271-85. PubMed ID: 22350326
    [Abstract] [Full Text] [Related]

  • 20. Identification and characterization of novel recombinant vaccine antigens for immunization against genital Chlamydia trachomatis.
    Coler RN, Bhatia A, Maisonneuve JF, Probst P, Barth B, Ovendale P, Fang H, Alderson M, Lobet Y, Cohen J, Mettens P, Reed SG.
    FEMS Immunol Med Microbiol; 2009 Mar 16; 55(2):258-70. PubMed ID: 19281568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.